Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Continued Prednisone in Steroid-Resistant Nephrotic Syndrome
NCT03298698Phase 3Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in Idiopathic nephrotic syndrome (INS), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), sponsored by Radboud University Medical Center. Status: unknown.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)minimal change disease (MCD)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03298698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298698.